Our clinical trials

Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types.

Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses.

Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)

Prospective biobanking study in ovarian, breast and head and neck cancer patients aiming at better understand the link between the molecular alterations of the tumor itself, its microenvironment and immune response.

Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control.

An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.